These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35144636)

  • 1. Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus.
    Sheng CS; Miao Y; Ding L; Cheng Y; Wang D; Yang Y; Tian J
    Lipids Health Dis; 2022 Feb; 21(1):19. PubMed ID: 35144636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Long-term HbA
    Sheng CS; Tian J; Miao Y; Cheng Y; Yang Y; Reaven PD; Bloomgarden ZT; Ning G
    Diabetes Care; 2020 Jun; 43(6):1185-1190. PubMed ID: 32229597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of blood lipid variability on mortality in patients with type 2 diabetes: a large single-center cohort study.
    Wang MC; Li CI; Liu CS; Lin CH; Yang SY; Li TC; Lin CC
    Cardiovasc Diabetol; 2021 Nov; 20(1):228. PubMed ID: 34823536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of blood lipid parameters variability with ischemic stroke in hypertensive patients.
    Huang YQ; Liu L; Liu XC; Lo K; Tang ST; Feng YQ; Zhang B
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1521-1532. PubMed ID: 33810958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
    Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
    Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
    Waters DD; Bangalore S; Fayyad R; DeMicco DA; Laskey R; Melamed S; Barter PJ
    J Clin Lipidol; 2018; 12(2):356-366. PubMed ID: 29310989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
    Keating GM
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combination lipid therapy in type 2 diabetes mellitus.
    ; Ginsberg HN; Elam MB; Lovato LC; Crouse JR; Leiter LA; Linz P; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm RH; Ismail-Beigi F; Bigger JT; Goff DC; Cushman WC; Simons-Morton DG; Byington RP
    N Engl J Med; 2010 Apr; 362(17):1563-74. PubMed ID: 20228404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
    Vakkilainen J; Steiner G; Ansquer JC; Perttunen-Nio H; Taskinen MR
    Diabetes Care; 2002 Mar; 25(3):627-8. PubMed ID: 11874962
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
    Zhu L; Hayen A; Bell KJL
    Cardiovasc Diabetol; 2020 Mar; 19(1):28. PubMed ID: 32138746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
    Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
    BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
    Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
    J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of medical therapies on retinopathy progression in type 2 diabetes.
    ; ; Chew EY; Ambrosius WT; Davis MD; Danis RP; Gangaputra S; Greven CM; Hubbard L; Esser BA; Lovato JF; Perdue LH; Goff DC; Cushman WC; Ginsberg HN; Elam MB; Genuth S; Gerstein HC; Schubart U; Fine LJ
    N Engl J Med; 2010 Jul; 363(3):233-44. PubMed ID: 20587587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.